Connection of metastasis-free survival in breast cancer patients and an expression vector of multidrug resistance genes in tumor during neoadjuvant chemotherapy
##article.numberofdownloads## 28
##article.numberofviews## 113
PDF (Русский)

Keywords

гены множественной лекарственной устойчивости
рак молочной железы
безметастатическая выживаемость
экспрессия генов

How to Cite

, , , , , , , , & . (2013). Connection of metastasis-free survival in breast cancer patients and an expression vector of multidrug resistance genes in tumor during neoadjuvant chemotherapy. Voprosy Onkologii, 70(1), 334–340. https://doi.org/10.37469/0507-3758-2013-59-3-334-340

Abstract

Previously, we showed the association of neoadjuvant chemotherapy (NAC) response with changing the expression vector (increase or decrease) of multidrug resistance genes (MDR) in breast tumors during chemotherapy. The aim of the present study was to evaluate the relation between changes in the expression vector of MDR genes and distant metastasis-free survival. Patients (n = 120) with breast cancer (Tj 4N 0 3M 0) treated by 2-4 cycles of NAC (CAX, FAC, and taxane regimes) and 4 cycles of adjuvant chemotherapy (FAC) were included. TaqMan-based quantitative reverse transcriptase PCR (qRT-PCR) was used to estimate the expression of the following MDR genes: АВСВ1, АВСС1, АВСС2, АВСС5. ABCG1, ABCG2, GSTP1, and MVP—in biopsies before NAC and in tumor samples after chemotherapy. Comparing the corresponding expression levels allowed us to identify the vector of expression change during NAC. The results showed that 5-year distant metastasis-free survival was 73-78% in patients with a decrease in ABCB1, ABCC2, and ABCG1 expression. The up-regulation of these genes during NAC was related to a significant decrease (up to 50-55%) in metastasis-free survival (Kaplan-Meier analysis: log-rank p value = 0.006-0.03). The association of changing the expression vector of MDR genes with metastasis-free survival did not depend on tumor size, lymph node involvement, histological form, receptor status, molecular subtype, and others clinicopathological parameters of breast cancer. The obtained data suggest that changing the expression vector of MDR genes in breast tumors during NAC may be used as a new potential prognostic marker of breast cancer. An increase in tumor expression of ABCB1. ABCC2, and ABCG1 during chemotherapy is a factor of poor prognosis, whereas down-regulation of these genes—a favorable prognostic marker.
https://doi.org/10.37469/0507-3758-2013-59-3-334-340
##article.numberofdownloads## 28
##article.numberofviews## 113
PDF (Русский)

References

Завьялова М.В., Литвяков Н.В., Гарбуков Е.Ю. и др. Взаимосвязь чувствительности опухоли к неоадъю-вантной химиотерапии с морфологическим строением первичного опухолевого узла при уницентрическом инфильтрирующем протоковом раке молочной железы // Сиб. онкол. журнал — 2008. — № 6. — С. 30-34.

Загрекова Е.И., Мещеряков А.А. Лекарственное лечение рака молочной железы // Рус. мед. журнал — 2002. — № 10. — С. 605-608.

Литвяков Н.В., Денисов Е.В., Гарбуков Е.Ю. и др. Экспрессия генов резистентности и маркеров химиочувствительности в опухоли молочной железы в процессе неоадъювантной химиотерапии // Сборник статей: Молекулярные и биологические технологии в медицинской практике. — 2011. — вып. 16. — С. 69-74.

Литвяков Н.В., Чердынцева Н.В., Цыганов М.М. и др. Ассоциация генетического полиморфизма с изменением экспрессии генов множественной лекарственной устойчивости в опухоли молочной железы в процессе неоадъювантной химиотерапии // Мед. генетика — 2011. — № 10. — С. 37-43.

Семиглазов В.Ф., Топузов Э. Э. Рак молочной железы. М.: МЕДпресс-информ, 2009. — 176 с.

Burger H., Foekens J.A., Look M.P et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins

and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response // Clin Cancer Res — 2003. — Vol. 9. — P 827-836.

Clark G.M. Prognostic and predictive factors for breast cancer // Breast Cancer — 1995. — Vol. 2. — P 79-89.

Eechoute K., Sparreboom A., Burger H. et al. Drug transporters and imatinib treatment: implications for clinical practice //Clinical Cancer Research — 2011. — Vol. 17. — P 406-415.

Filipits M., Pohl G., Rudas M. et al. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group //J. Clin. Oncol. - 2005. - Vol. 23. - P.1161-1168.

Glubb D.M., Innocenti F. Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters // WIREs Syst Biol Med - 2011-Vol. 3. - P. 299-313.

Gottesman M.M., Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research // FEBS letters - 2006. - Vol. 580.- P. 9981009.

Kanzaki A., Toi M., Nakayama K. et al. Expression of multidrug resistance-related transporters in human breast carcinoma // Jpn J Cancer Res. 2001. - Vol. 92. -P. 452-458.

Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations // J. Amer. Statist. Assoc. -1958 - Vol. 53. - P. 457-481.

Leonessa F, Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. // Endocr Relat Cancer - 2003. - Vol. 10. - P. 43-73.

Litviakov N.V., Cherdyntseva N.V., Tsyganov M.M. et al. Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response // Cancer Chemother. Pharmacol. - 2013. - Vol. 71. -P. 153-163.

Moureau-Zabotto L., Ricci S., Lefranc J.P. et al. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients // Br J Cancer - 2006. - Vol. 94. - P. 473-480.

Perel'muter V.M., Zav'ialova M.V., Vtorushin S.V. et al. [Genetic and clinical and pathological characteristics of breast cancer in premenopausal and postmenopausal women] // Adv Gerontol - 2008. - Vol. 21. - P. 643-653.

Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR // Nucleic Acids Res - 2001. - Vol. 29. - P. 45.

Reed K., Parissenti A.M. Epigenetic Regulation of ABCB1 Transporter Expression and Function // Current Pharmacog - 2010. - Vol. 8. - P. 218-231.

Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview // Advanced Drug Delivery Rev. - 2003. -Vol. 55. - P. 3-29.

Schwartz G.F, Hortobagyi G.N. Proceedings of the Consensus Conference on Neoadjuvant Chemotherapy in Carcinoma of the Breast, April 26-28, 2003, Philadelphia, Pennsylvania // The Breast Journal - 2004. - Vol.10. -P. 273-294.

Sharma G., Mirza S., Parshad R. et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients // Clin Biochem - 2010. -Vol. 43. - P. 373-379.

Szakacs G., Annereau J.P., Lababidi S. et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells // Cancer Cell - 2004. - Vol. 6. -P. 129-137.

Wind N.S., Holen I. Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies // Int. J. Breast Cancer 201Г967419. - P. 1-12.

Wolmark N., Wang J., Mamounas E. et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 // JNCI Monographs - 2001. -P. 96-102.

Zavyalova M., Perelmuter V., Vtorushin S., et al. The presence of alveolar structures in invasive ductal NOS breast carcinoma is associated with lymph node metastasis // Diagnost. Cytopathol. 2013. - Vol. 41 (3). - P. 279-282.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...